University of Leeds, Leeds, UK.
Expert Opin Pharmacother. 2010 Dec;11(17):2929-32. doi: 10.1517/14656566.2010.529900. Epub 2010 Oct 23.
Luteinizing hormone releasing hormone (LH RH) agonists are the major agent for androgen deprivation therapy in advanced and metastatic prostate cancer. They also have a role in endometriosis, uterine fibroids and central precocious puberty.
Triptorelin embonate 22.5 mg is a new, sustained-release, 6-month formulation of an LH RH agonist. It possesses longer duration of action than the current standard 3-month preparation and appears to have similar efficacy and side effects.
The use of LH RH agonists for androgen deprivation in prostate cancer has increased considerably in the last 20 years. Recent work has shown that some of this usage has constituted overtreatment and it is within these newer paradigms of therapy that the new 6-month preparation is situated.
The new 6-month LH RH preparation - triptorelin embonate - will be of help in several key areas of therapy for prostate cancer, notably as an adjunct to radiation therapy and chemotherapy. It possesses a similar effect, but with fewer side effects, than those that are now commonly available.
促黄体激素释放激素（LH RH）激动剂是晚期和转移性前列腺癌雄激素剥夺治疗的主要药物。它们在子宫内膜异位症、子宫肌瘤和中枢性性早熟中也有作用。
恩杂鲁胺 22.5 毫克是一种新的、缓释的、6 个月的 LH RH 激动剂制剂。它的作用持续时间比目前的标准 3 个月制剂更长，并且似乎具有相似的疗效和副作用。
在过去的 20 年中，LH RH 激动剂在前列腺癌的雄激素剥夺治疗中的使用有了相当大的增加。最近的研究表明，其中一些使用构成了过度治疗，而这种新的 6 个月制剂正是在这些新的治疗范例中出现的。
新的 6 个月 LH RH 制剂——恩杂鲁胺——将在前列腺癌治疗的几个关键领域提供帮助，特别是作为放射治疗和化学治疗的辅助药物。它具有相似的效果，但副作用比目前常用的药物更少。
